natgillin/translations-raw huggingface dataset:
However, any amendment affecting the essential elements of these statutes, and in particular amendments to Articles 3, 4, 6, 7, 11, 13, 21, 24 and 25 thereof, shall be adopted in accordance with Article 172 of the Treaty.
Vse spremembe bistvenih elementov tega statuta, in zlasti spremembe členov 3, 4, 6, 7, 11, 13, 21, 24 in 25 Statuta, pa se sprejmejo v skladu s členom 172 Pogodbe.
At the end of the period provided for in Article 1(1) of this Regulation, or following an amendment pursuant to Article 11(2) of this Regulation, the ENIAC Joint Undertaking shall be wound up.
Likvidacija Skupnega podjetja ENIAC se izvede ob koncu obdobja, določenega v členu 1(1) te uredbe, ali na podlagi spremembe v skladu s členom 11(2) te uredbe.
The winding-up procedure shall be automatically triggered if the Commission withdraws from the ENIAC Joint Undertaking.
Postopek likvidacije se začne samodejno, če se Komisija umakne iz Skupnega podjetja ENIAC.
For the purpose of conducting the proceedings involved in liquidating the ENIAC Joint Undertaking, the governing board shall appoint one or more liquidators, who shall comply with the decisions of the governing board.
Za vodenje postopkov v zvezi z likvidacijo Skupnega podjetja ENIAC upravni odbor imenuje enega ali več likvidacijskih upraviteljev, ki spoštujejo odločitve upravnega odbora.
When the ENIAC Joint Undertaking is being wound up, it shall return to the host State any physical support item made available by the host State in accordance with the host agreement referred to in Article 17 of this Regulation.
Ko je Skupno podjetje ENIAC likvidirano, državi gostiteljici vrne vso fizično podporo, ki ji jo je ta dala na voljo v skladu s sporazumom o gostovanju iz člena 17 te uredbe.
When any physical asset has been dealt with as provided for in paragraph 4, any further assets shall be used to cover the liabilities of the ENIAC Joint Undertaking and the costs relating to its winding-up.
Po vrnitvi fizičnega premoženja, kot je določeno v odstavku 4, se vsa nadaljnja sredstva uporabijo za kritje obveznosti Skupnega podjetja ENIAC in stroškov, povezanih z njegovo likvidacijo.
Any surplus shall be distributed among the members existing at the time of the winding-up in proportion to their actual contribution to the ENIAC Joint Undertaking.
Vsi presežki se porazdelijo med člane, obstoječe v trenutku likvidacije, in sicer sorazmerno z njihovim dejanskim prispevkom k Skupnemu podjetju ENIAC.
Remaining assets shall be distributed to the members existing at the time of the winding-up in proportion to their actual contribution to the ENIAC Joint Undertaking.
Preostala sredstva se porazdelijo med člane, obstoječe v trenutku likvidacije, in sicer sorazmerno z njihovim dejanskim prispevkom k Skupnemu podjetju ENIAC.
An ad hoc procedure shall be set up to ensure the appropriate management of any grant agreement and service and supply contract concluded by the ENIAC Joint undertaking, with a duration longer than the duration of the ENIAC Joint Undertaking.
Vzpostavi se ad hoc postopek za zagotovitev primernega upravljanja vsakršnega sporazuma o dodelitvi sredstev ter pogodbe o naročilu blaga in storitev, ki jih sklene Skupno podjetje ENIAC za obdobje, daljše od obdobja obstoja Skupnega podjetja ENIAC.
The ENIAC Joint Undertaking shall contribute to the implementation of the Seventh Framework Programme and the theme ‘Information and Communication Technologies’ of the Specific Programme ‘Cooperation’. It shall, in particular:
Skupno podjetje ENIAC prispeva k izvajanju Sedmega okvirnega programa in teme „Informacijske in komunikacijske tehnologije“ posebnega programa „Sodelovanje“ Naloge Skupnega podjetja ENIAC so zlasti:
Corrigendum to Council Regulation (EC) No 72/2008 of 20 December 2007 setting up the ENIAC Joint Undertaking
Popravek Uredbe Sveta (ES) št. 72/2008 z dne 20. decembra 2007 o ustanovitvi „Skupnega podjetja ENIAC“
(Official Journal of the European Union L 30 of 4 February 2008)
(Uradni list Evropske unije L 30 z dne 4. februarja 2008)
On page 35, Annex, ‘Statutes of the ENIAC Joint Undertaking’, Article 19(3):
Stran 35, Priloga – Statut skupnega podjetja ENIAC, člen 19(3) se spremeni:
The annual implementation plan shall specify the plan for the execution of all the activities of the ENIAC Joint Undertaking for a particular year, including planned calls for proposals and actions needing to be implemented through calls for tenders.
Letni izvedbeni načrt določa načrt za izvedbo vseh dejavnosti Skupnega podjetja ENIAC za določeno leto, vključno s predvidenimi razpisi za zbiranje predlogov in ukrepi, ki jih je treba izvesti z razpisi za pridobivanje ponudb.
on page 37, Annex, ‘Statutes of the ENIAC Joint Undertaking’, Article 23, point 3.4.2:
Stran 37, Priloga – Statut skupnega podjetja ENIAC, člen 23 (3.4.2.) se spremeni:
Subject to its obligations concerning confidentiality, where a project participant is required to pass on its obligations to provide access rights, it shall give at least 45 days' prior notice to the other participants of the envisaged transfer, …’,
Ob upoštevanju obveznosti v zvezi z zaupnostjo udeleženec projekta takrat, ko se od njega zahteva prenos njegovih obveznosti, da bi zagotovil pravice dostopa, ostale udeležence predvidenega prenosa obvesti vsaj 45 dni prej (…)“
Subject to its obligations concerning confidentiality, where a project participant is required to pass on its obligations to provide access rights, it shall give at least 45 days' prior notice to the other participants of the envisaged transfer, …
Ob upoštevanju obveznosti v zvezi z zaupnostjo udeleženec projekta takrat, ko se od njega zahteva prenos njegovih obveznosti, da bi zagotovil pravice dostopa, ostale udeležence predvidenega prenosa obvesti vsaj 45 dni prej (…)“.
The participants may, by written agreement, agree on a different time limit or waive their right to prior notice in the case of transfers of ownership from one participant to a specifically identified third party.’
Udeleženci se lahko s pisnim dogovorom dogovorijo o drugačnem roku ali se odpovejo svoji pravici do predhodnega obvestila v primeru prenosa lastništva z enega udeleženca na točno določeno tretjo stranko.
Council Regulation (EC) No 73/2008
Uredba Sveta (ES) št. 73/2008
setting up the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines
o ustanovitvi Skupnega podjetja za izvajanje skupne tehnološke pobude za inovativna zdravila
Decision No 1982/2006/EC of the European Parliament and of the Council of 18 December 2006 concerning the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007-2013) (hereinafter referred to as the Seventh Framework Programme) provides for a Community contribution for the establishment of long-term public private partnerships in the form of Joint Technology Initiatives which could be implemented through Joint Undertakings within the meaning of Article 171 of the Treaty.
Sklep št. 1982/2006/ES Evropskega parlamenta in Sveta z dne 18. decembra 2006 o Sedmem okvirnem programu Evropske skupnosti za raziskave, tehnološki razvoj in predstavitvene dejavnosti (2007–2013), (v nadaljnjem besedilu „Sedmi okvirni program“), določa prispevek Skupnosti k vzpostavitvi dolgoročnih javno-zasebnih partnerstev v obliki skupnih tehnoloških pobud, ki bi se lahko izvajale prek skupnih podjetij v smislu člena 171 Pogodbe.
These Joint Technology Initiatives result from the work of European Technology Platforms, already set up under the Sixth Framework Programme, and cover selected aspects of research in their field.
Te skupne tehnološke pobude izhajajo iz dela, opravljenega v okviru evropskih tehnoloških platform, ki so bile vzpostavljene že v okviru Šestega okvirnega programa in vključujejo izbrane vidike raziskav na svojem področju.
They should combine private sector investment and European public funding, including funding from the Seventh Framework Programme.
V njih bi se morale povezovati naložbe zasebnega sektorja in javno financiranje na evropski ravni, vključno s financiranjem iz Sedmega okvirnega programa.
Council Decision/2006/971/EC of 19 December 2006 concerning the specific programme ‘Cooperation’ implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) (hereinafter referred as the Specific Programme Cooperation) underlines the need for ambitious pan-European public private partnerships to accelerate the development of major technologies, large research actions at Community level including, in particular, Joint Technology Initiatives.
V Odločbi Sveta 2006/971/ES z dne 19. decembra 2006 o posebnem programu „Sodelovanje“ za izvajanje Sedmega okvirnega programa Evropske skupnosti za raziskave, tehnološki razvoj in predstavitvene dejavnosti (2007–2013) (v nadaljnjem besedilu „posebni program Sodelovanje“) je poudarjen pomen velikopoteznih vseevropskih javno-zasebnih partnerstev za pospešitev razvoja poglavitnih tehnologij in obsežnih raziskovalnih dejavnosti na ravni Skupnosti, zlasti tudi skupnih tehnoloških pobud.
The Lisbon Growth and Jobs Agenda underscores the need to develop favourable conditions for investment in knowledge and innovation in Europe to boost competitiveness, growth and jobs in the Community.
V Lizbonski agendi za rast in delovna mesta je poudarjena potreba po razvoju ugodnih pogojev za naložbe v znanje in inovacije v Evropi za spodbujanje konkurenčnosti, rasti in zaposlovanja.
In its conclusions of 13 March 2003, of 22 September 2003 and of 24 September 2004, the Council highlighted the importance of further developing actions following the 3 % Action Plans, including the development of new initiatives aimed at intensifying cooperation between industry and the public sector in funding research to enhance trans-national public-private links.
V sklepih z dne 13. marca 2003, 22. septembra 2003 in 24. septembra 2004 je Svet poudaril pomen nadaljnjih razvojnih ukrepov na podlagi akcijskih načrtov 3 % („3 % Action Plans“), tudi razvijanja novih pobud, katerih cilj bi bil okrepiti sodelovanje med industrijo in javnim sektorjem pri financiranju raziskav, da bi tako okrepili nadnacionalne povezave med javnim in zasebnim sektorjem.
In its conclusions of 4 December 2006 and of 19 February 2007, the Competitiveness Council and in its conclusions of 9 March 2007 the European Council invited the Commission to present proposals for the setting up of Joint Technology Initiatives for such initiatives that have reached an appropriate stage of preparedness.
Svet za konkurenčnost, s sklepi z dne 4. decembra 2006 in 19. februarja 2007, in Evropski svet, s sklepi z dne 9. marca 2007, sta pozvala Komisijo, naj predstavi predloge o vzpostavitvi skupnih tehnoloških pobud za tiste pobude, ki so že dobro pripravljene.
The European Federation of Pharmaceutical Industries and Associations (hereinafter referred to as EFPIA) took the lead in establishing the European Technology Platform on Innovative Medicines under the Sixth Framework Programme.
„Evropska federacija farmacevtske industrije in združenj“ (v nadaljnjem besedilu „EFPIA“) je prevzela vodilno vlogo pri ustanavljanju evropske tehnološke platforme za inovativna zdravila v okviru Šestega okvirnega programa.
It developed a Strategic Research Agenda, based on an extensive consultation with public and private stakeholders.
Po obsežnih posvetovanjih z zainteresiranimi stranmi iz javnega in zasebnega sektorja je pripravila strateški raziskovalni program.
The Strategic Research Agenda described the research bottlenecks in the drug development process and recommends the scientific direction for a Joint Technology Initiative on Innovative Medicines.
V zadevnem strateškem raziskovalnem programu so opisana raziskovalna ozka grla v procesu razvoja zdravil, vsebuje pa tudi priporočila o znanstveni usmerjenosti skupne tehnološke pobude za inovativna zdravila.
The Joint Technology Initiative on Innovative Medicines responds to the Commission Communication of 1 July 2003‘A Stronger European-based Pharmaceutical Industry for the Benefit of the Patient — A Call for Action’ and in particular to the recommendation regarding access to innovative medicines to secure the development of a competitive innovative-based industry.
Skupna tehnološka pobuda za inovativna zdravila je odgovor na sporočilo Komisije z dne 1. julija 2003„Močnejša farmacevtska industrija s sedežem v Evropi v korist bolnika – Poziv k ukrepanju“ in zlasti na priporočilo glede dostopa do inovativnih zdravil, da se zagotovi razvoj konkurenčne industrije, ki bo temeljila na inovacijah.
This Communication was a response to the Report ‘Stimulating Innovation and Improving the EU Science Base’ adopted on 7 May 2002 by the High Level Group on innovation and provision of medicines — G10 Medicines.
To sporočilo je bilo pripravljeno v odziv na poročilo Skupine na visoki ravni za inovacije in oskrbo z zdravili – zdravila G10 z naslovom „Spodbujanje inovacij in izboljšanje znanstvene baze EU“, sprejeto 7. maja 2002.
This Joint Technology Initiative also responds to the Commission Communication of 23 January 2002‘Life Sciences and Biotechnology — a strategy for Europe (2002)’.
Prav tako je ta skupna tehnološka pobuda odgovor na sporočilo Komisije z dne 23. januarja 2002„Bioznanost in biotehnologija – strategija za Evropo (2002)“.
The Joint Technology Initiative on Innovative Medicines also replies to the need for action as identified in the Report ‘Creating an Innovative Europe’ of January 2006.
Skupna tehnološka pobuda za inovativna zdravila je tudi odgovor na potrebo po ukrepanju, izraženo v poročilu „Ustvarjanje inovativne Evrope“ iz januarja 2006.
This report identifies pharmaceuticals as a key strategic area and it stresses the need for the Joint Technology Initiative on Innovative Medicines at European level.
V tem poročilu je področje zdravil označeno kot ključno strateško področje, poudarjena je tudi potreba po skupni tehnološki pobudi za inovativna zdravila na evropski ravni.
The Joint Technology Initiative on Innovative Medicines should be a public private partnership aiming at increasing investments in the biopharmaceutical sector in Europe in the Members States and countries associated within the Seventh Framework Programme.
Skupna tehnološka pobuda za inovativna zdravila bi morala imeti obliko javno-zasebnega partnerstva, njen namen pa bi moral biti povečanje naložb v biofarmacevtski sektor v Evropi v državah članicah in državah, pridruženih k Sedmemu okvirnemu programu.
It should provide socioeconomic benefits for European citizens, contribute to the health of European citizens, increase the competitiveness of Europe and help to establish Europe as the most attractive place for biopharmaceutical research and development.
Evropskim državljanom bi morala zagotoviti socialno-ekonomske koristi, prispevati k njihovemu zdravju, izboljšati bi morala evropsko konkurenčnost in pripomoči k uveljavljanju Evrope kot najbolj privlačnega prostora za biofarmacevtske raziskave in razvoj.
The objective of the Joint Technology Initiative on Innovative Medicines should be to foster collaboration between all stakeholders such as industry, public authorities (including regulators), organisations of patients, academia and clinical centres.
Cilj skupne tehnološke pobude za inovativna zdravila bi moral biti spodbujanje sodelovanja med vsemi zainteresiranimi stranmi, kot so industrija, javni organi (vključno z regulatornimi organi), organizacije bolnikov, akademski krogi in klinični centri.
The Joint Technology Initiative on Innovative Medicines should define a commonly agreed research agenda (hereinafter referred to as Research Agenda) closely following the recommendations of the Strategic Research Agenda developed by the European Technology Platform on Innovative Medicines which identified efficacy, safety, knowledge management and training as important areas.
V okviru skupne tehnološke pobude za inovativna zdravila bi bilo treba določiti skupno dogovorjeni raziskovalni program (v nadaljnjem besedilu „raziskovalni program“), ki bi natančno upošteval priporočila iz strateškega raziskovalnega programa, ki ga je razvila Evropska tehnološka platforma za inovativna zdravila; ta je kot pomembna področja navedla učinkovitost, varnost, upravljanje znanja in usposabljanje.
The Joint Technology Initiative on Innovative Medicines should propose a coordinated approach to overcome identified research bottlenecks in the drug development process, and to support pre-competitive pharmaceutical research and development, in order to accelerate the development of safe and more effective medicines for patients.
V okviru skupne tehnološke pobude za inovativna zdravila bi bilo treba predlagati usklajen pristop, s katerim bi odpravili ugotovljena raziskovalna ozka grla v procesu razvoja zdravil in zagotovili podporo predkonkurenčnim farmacevtskim raziskavam in razvoju ter tako pospešili razvoj varnih in učinkovitejših zdravil za bolnike.
In the present context ‘pre-competitive pharmaceutical research and development’ should be understood as research on the tools and methodologies used in the drug development process.
V zadevnem kontekstu bi bilo treba predkonkurenčne farmacevtske raziskave in razvoj razumeti kot raziskave, usmerjene v orodja in metodologije, ki se uporabljajo v procesu razvoja zdravil.
The Joint Technology Initiative on Innovative Medicines should deliver new approaches, methods and technologies, improve knowledge management of research results and data, and support the training of professionals.
Skupna tehnološka pobuda za inovativna zdravila bi morala obroditi nove pristope, metode in tehnologije, boljše upravljanje znanja o rezultatih raziskav in podatkih v zvezi z njimi ter podpreti usposabljanje strokovnjakov.
To this end, it is necessary to set up a Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (hereinafter referred to as the IMI Joint Undertaking) as a legal entity.
V ta namen je treba ustanoviti Skupno podjetje za izvajanje skupne tehnološke pobude o inovativnih zdravilih (v nadaljnjem besedilu „Skupno podjetje IMI“) kot pravno osebo.
The objective of the IMI Joint Undertaking should be achieved through support of research activities by pooling resources from the public and private sectors.
Cilj Skupnega podjetja IMI bi morali doseči s podporo raziskovalnim dejavnostim, in sicer z združevanjem sredstev iz javnega in zasebnega sektorja.
To this end, the IMI Joint Undertaking should be capable of organising competitive calls for proposals for supporting the research activities.
V ta namen bi moralo biti skupno podjetje IMI sposobno organizirati konkurenčne razpise za zbiranje predlogov projektov v podporo raziskovalnim dejavnostim.
Such research activities should respect fundamental ethical principles applicable in the Seventh Framework Programme.
Te raziskovalne dejavnosti bi morale upoštevati temeljna etična načela, ki se uporabljajo v okviru Sedmega okvirnega programa.
The IMI Joint Undertaking should be set up for a period up to 31 December 2017 to ensure the appropriate management of research activities initiated but not concluded during the Seventh Framework Programme (2007 to 2013).
Skupno podjetje IMI bi bilo treba ustanoviti za obdobje do 31. decembra 2017 in tako zagotoviti ustrezno upravljanje raziskovalnih dejavnosti, začetih, ne pa tudi zaključenih v obdobju Sedmega okvirnega programa (2007–2013).
The IMI Joint Undertaking should be a body set up by the Community and discharge for the implementation of its budget should be given by the European Parliament, on the recommendation of the Council, in accordance with Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the budget of the European Communities (hereinafter referred to as the Financial Regulation) taking however into account the specificities resulting from the nature of joint technology initiatives as public-private partnerships and in particular from the private sector contribution to the budget.
Skupno podjetje IMI bi moralo biti organ, ki ga ustanovi Skupnost, razrešnico za izvajanje njegovega proračuna pa bi moral dati Evropski parlament na priporočilo Sveta, v skladu z Uredbo Sveta (ES, Euratom) št. 1605/2002 z dne 25. junija 2002 o finančni uredbi, ki se uporablja za splošni proračun Evropskih skupnosti (v nadaljnjem besedilu „Finančna uredba“) vendar ob upoštevanju posebne narave skupnih tehnoloških pobud kot javno-zasebnih partnerstev in prispevkov zasebnega sektorja v zadevni proračun.
Founding members of the IMI Joint Undertaking should be the Community and EFPIA.
Ustanovni članici Skupnega podjetja IMI bi morali biti Skupnost in EFPIA.
EFPIA is a non-profit organisation representing the research based pharmaceutical industry in Europe.
EFPIA je nepridobitna organizacija, ki zastopa znanstvenoraziskovalno farmacevtsko industrijo v Evropi.
The aim of EFPIA is to ensure and promote the technological and economic development of the pharmaceutical industry in Europe.
Cilj EFPIA je zagotavljati in spodbujati tehnološki in gospodarski razvoj farmacevtske industrije v Evropi.
EFPIA is open for membership to national associations of research-based pharmaceutical companies, as well as directly to research-based pharmaceutical companies.
Člani EFPIA so lahko nacionalna združenja znanstvenoraziskovalnih farmacevtskih družb in neposredno znanstvenoraziskovalne farmacevtske družbe.
It applies general principles of openness and transparency for membership ensuring a wide industrial involvement.
Federacija sledi splošnemu načelu odprtosti in preglednosti članstva, kar zagotavlja široko vključenost industrije.
The IMI Joint Undertaking should be open to new members.
Skupno podjetje IMI bi moralo biti odprto za nove člane.
The rules for organisation and operation of the IMI Joint Undertaking should be laid down in the Statutes of the IMI Joint Undertaking as part of this Regulation.
Pravila organizacije in delovanja skupnega podjetja IMI bi morala biti določena v statutu skupnega podjetja IMI, ki je del te uredbe.
A letter of commitment concerning the Statutes of the IMI Joint Undertaking has been signed by EFPIA and its research based pharmaceutical companies that are members of EFPIA.
Izjavo o zavezi glede statuta skupnega podjetja IMI so podpisale EFPIA in znanstvenoraziskovalne farmacevtske družbe, ki so njene članice.
The research activities should be covered by funding from the Community and at least on an equal level by resources from the research based pharmaceutical companies that are members of EFPIA.
Raziskovalne dejavnosti bi morale biti financirane iz virov Skupnosti, vsaj v enakem obsegu pa bi bilo njihovo financiranje treba zagotoviti iz virov znanstvenoraziskovalnih farmacevtskih družb, ki so članice EFPIA.
Further financing options may be available, inter alia, from the European Investment Bank, in particular through the Risk-Sharing Finance Facility developed jointly with the EIB and the Commission pursuant to Annex III to Decision/2006/971/EC.
Na voljo so lahko tudi druge možnosti financiranja, med drugim iz Evropske investicijske banke, predvsem iz Sklada za financiranje na osnovi delitve tveganja, ki sta ga skupaj razvili EIB in Komisija na podlagi Priloge III k Odločbi Sveta 2006/971/ES.
The running costs of the IMI Joint Undertaking should be covered in equal amount by EFPIA and the Community.
Stroške poslovanja Skupnega podjetja IMI bi morali v enakih zneskih kriti EFPIA in Skupnost.
To ensure an equal partnership, the research based pharmaceutical companies that are members of EFPIA activities should not be eligible to receive financial support from the IMI Joint Undertaking.
Da bi bilo partnerstvo zares enakovredno, znanstvenoraziskovalne farmacevtske družbe, ki kot članice sodelujejo pri dejavnostih EFPIA, ne bi smele biti upravičene do finančne podpore iz Skupnega podjetja IMI.